Drug Profile

Research programme: adeno-associated virus gene therapy - Tenaya Therapeutics

Alternative Names: DWORF gene therapy program - Tenaya Therapeutics

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Aug 2024 No recent reports of development identified for preclinical development in Cardiomyopathies in USA (Parenteral)
16 Aug 2024 Preclinical trials in Heart failure in USA (Parenteral) (Tenaya Therapeutics pipeline, August 2024)
08 Aug 2024 Tenaya receives a notice of allowance from the U.S. Patent and Trademarks Office covering composition of matter protections for DWORF gene therapy program for the treatment of Cardiomyopathy and Heart failure

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com